Defying the Market Downturn: HLB and Daewon Pharmaceutical Surge on Earnings Growth Expectations ...
- created on 11/02/2026 6:00:12 AM
- modified on 11/02/2026 6:00:12 AM
This article was released as Pharm Edaily Premium Content on 11/02/2026 6:00:12 AM
Subscribe
Unauthorized reproduction or distribution is illegal and subject to criminal penalties.
Pharm Edaily enforces a zero-tolerance policy and will take strict action.
Pharm Edaily enforces a zero-tolerance policy and will take strict action.
Premium Content
이 기사는 유료 구독자를 위한 프리미엄 콘텐츠입니다.
유료 구독(플래티넘)을 통해 더 많은 콘텐츠를 만나보세요.
This article is premium content for paid subscribers.
Subscribe to paid subscription (Platinum) for full access.
저작권자 © 팜이데일리 - 기사 무단전재, 재배포시 법적인 처벌을 받을 수 있습니다.
![유한양행, 렉라자 로열티 기대 낮아졌다[인베스트 바이오]](https://image.edaily.co.kr/images/vision/files/NP/S/2026/10/PS26103100129b.jpg)
![하락장 속에도 수익성 확대 기대감 HLB·대원제약↑ [바이오맥짚기]](https://image.edaily.co.kr/images/Photo/files/NP/S/2026/11/PS26110200063b.jpg)
![[바이오스터디] 약 대신 앱을 처방? 국내 최초 비대면 임상 허가받은 웰트의 '디지털 치료제' 사업](https://i.ytimg.com/vi/cYktLIu8vSE/mqdefault.jpg)
SPOTLIGHT